Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Saint-Herblain
Clinical trial register · France

Clinical Trials in Saint-Herblain, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9722 matching records held by the registry are in this view. Synced 29 Oct 2026, 03:20 UTC
9722
Studies in scope
all four open statuses
6047
Recruiting now
open to new participants
1031
Lead sponsors
across recruiting studies
Top sites
Paris 2823 Lyon 1395 Bordeaux 1389 Marseille 1291 Lille 1281
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institut Cancerologie de l'Ouest17 AstraZeneca15 Novartis Pharmaceuticals12 Bristol-Myers Squibb11 Merck Sharp & Dohme LLC10
Site location
Paris2823 Lyon1395 Bordeaux1389 Marseille1291 Lille1281
All 809 locations
Target enrolment
to

Trials with a site in Saint-Herblain

243 of 9722 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Not yet open
Institut Cancerologie de l'Ouest
Phase 1
24
Saint-Herblain
2027-01
Not yet open
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)
NCT07782112Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer
DrugEnzalutamide
Ente Ospedaliero Cantonale, Bellinzona
Phase 3
140
Bordeaux, Lille, Saint-Etienne, Saint-Herblain, Villejuif
2026-11
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin
Daiichi Sankyo
Phase 1/2
400
Marseille, Montpellier, Paris, Rennes, Saint-Herblain, Suresnes, Vandœuvre-lès-Nancy, Villejuif
2026-10-13
Not yet open
Hospices Civils de Lyon
Not applicable
122
Bron, Paris, Pessac, Saint-Herblain, Strasbourg
2026-10-10
Not yet open
Celtic Biotech Ltd
Phase 1
24
Saint-Herblain
2026-10
Not yet open
Institut Cancerologie de l'Ouest
Early Phase 1
15
Angers, Saint-Herblain
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Saint-Herblain, Montpellier, Paris, Bordeaux, Dijon, Lyon, Marseille
2026-09-29
Not yet open
UNICANCER
Phase 2
51
Bordeaux, Lyon, Marseille, Nice, Paris, Rennes, Saint-Herblain, Toulouse
2026-09-18
Recruiting
Bristol-Myers Squibb
Phase 2
160
Nice, Montpellier, Villejuif, Grenoble, Marseille, Paris, Saint-Herblain
2026-09-10
Not yet open
Institut Cancerologie de l'Ouest
Not applicable
60
Saint-Herblain
2026-09
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Atezolizumab·Carboplatin
SystImmune Inc.
Phase 3
550
Créteil, Lyon, Marseille, Paris, Saint-Herblain
2026-08-04
Recruiting
Pfizer
Phase 3
954
Saint-Herblain, Montpellier
2026-06-10
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Bron, Saint-Herblain, Villejuif
2026-06-08
Recruiting
Institut Cancerologie de l'Ouest
Not applicable
18
Saint-Herblain
2026-06-01
Recruiting
Novo Nordisk A/S
Phase 3
2,500
Bois-Guillaume, Colmar, Le Coudray, Paris, Pessac, Pierre-Bénite, Saint-Herblain, Vénissieux
2026-05-21
Recruiting
Novartis Pharmaceuticals
Phase 1
24
Bordeaux, Saint-Herblain
2026-05-19
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Nice, Strasbourg, Pessac, Besançon, La Tronche, Saint-Herblain, Angers, Bron
2026-05-06
Not yet open
Institut Cancerologie de l'Ouest
Observational
1,000
Saint-Herblain
2026-05
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Besançon, Brest, Dijon, Lyon, Paris, Pierre-Bénite, Saint-Herblain, Strasbourg
2026-04-17
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
60
Villejuif, Bordeaux, Dijon, Marseille, Paris, Saint-Herblain, Vandœuvre-lès-Nancy
2026-03-25
Recruiting
Elsan
Phase 3
40
Saint-Herblain
2026-03-24
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Angers, Bois-Guillaume, Dijon, Paris, Pessac, Pierre-Bénite, Poitiers, Saint-Herblain
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Bordeaux, Lyon Cedex08, Dijon, Montpellier, Saint-Herblain, Toulouse, Lille, Villejuif
2026-03-16
Recruiting
Nantes University Hospital
Not applicable
560
Lyon, Nantes, Nîmes, Paris, Poitiers, Saint-Herblain, Villejuif
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Nice, Pessac, Lille, Montpellier, La Tronche, Saint-Herblain, Toulouse, Villefranche-sur-Saône
2026-03-12
Recruiting
Hoffmann-La Roche
Phase 2
360
Strasbourg, Nîmes, Bordeaux, Toulouse, Montpellier, Saint-Herblain, Nancy, Clermont-Ferrand
2026-03-10
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Paris, Pierre-Bénite, Saint-Herblain, Toulouse, Vénissieux
2026-02-24
Recruiting
Helix Surgical
Observational
446
Saint-Herblain
2026-01-28
Not yet open
Institut du Cancer de Montpellier - Val d'Aurelle
Not applicable
120
Dijon, Montpellier, Rennes, Saint-Herblain, Lille, Villeurbanne, Rouen, Avignon
2026-01-15
Recruiting
dsm-firmenich Switzerland AG
Not applicable
200
Saint-Herblain
2026-01-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Pessac, Besançon, Toulouse, Rouen, Suresnes, Saint-Herblain, Lorient, Lille
2025-12-31
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Bron, Marseille, Caen, Toulouse, Lyon, Saint-Herblain
2025-12-17
Recruiting
Ipsen
Phase 1/2
114
Lyon, Saint-Herblain, Villejuif
2025-12-05
Recruiting
Institut Cancerologie de l'Ouest
Not applicable
12
Saint-Herblain
2025-12-05
Recruiting
GlaxoSmithKline
Phase 3
450
Angers, Bordeaux, Lille, Lyon, Marseille, Saint-Herblain, Toulouse, Villejuif
2025-12-03
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Avignon, Le Mans, Lille, Marseille, Paris, Rouen, Saint-Herblain, Villejuif
2025-12-03
Recruiting
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899Catecholaminergic Polymorphic Ventricular Tachycardia
DrugCRD-4730
Cardurion Pharmaceuticals, Inc.
Phase 2
12
Bron, Paris, Saint-Herblain
2025-12-01
Active, closed
Institut Cancerologie de l'Ouest
Observational
22,000
Lille, Lyon, Paris, Saint-Herblain
2025-12-01
Recruiting
AbbVie
Phase 1
285
Saint-Herblain, Lyon
2025-11-27
Recruiting
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
NCT06846346Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Advanced Gastric Adenocarcinoma
DrugsTaxol·Ivonescimab·Folfox·Irinotecan
UNICANCER
Phase 2
88
Lyon, Marseille, Reims, Saint-Herblain
2025-11-20
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Amiens Cedex1, Bordeaux, Bron, Limoges, Montpellier, Paris, Saint-Herblain, Strasbourg
2025-11-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Strasbourg, Toulouse, Lille, La Tronche, Saint-Herblain, Bron, Villejuif, Marseille
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
300
Saint-Herblain, Vénissieux
2025-11-05
Recruiting
AstraZeneca
Phase 3
400
Boulogne-Billancourt, Lyon, Marseille, Saint-Herblain, Toulouse
2025-10-31
Recruiting
GlaxoSmithKline
Phase 1/2
47
Lyon, Saint-Herblain, Villejuif
2025-10-20
Recruiting
Study on a Prosthetic Foot With Adjustable Heel Height
NCT07214493Lower Limb Amputation Above Knee, Lower Limb Amputation Below Knee
Otto Bock France SNC
Not applicable
30
Concarneau, Échirolles, Nancy, Saint-Herblain, Valenton
2025-10-08
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
Montpellier, Paris, Saint-Herblain
2025-10-06
Recruiting
AstraZeneca
Phase 1/2
283
Lyon, Montpellier, Saint-Herblain, Suresnes, Villejuif
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Nice, Strasbourg, Bordeaux, Lyon Cedex08, Brest, Suresnes, Saint-Herblain, Marseille
2025-09-30
Recruiting
Pfizer
Phase 3
680
Brest, Toulouse, Rennes, Saint-Herblain, Lille, Villejuif, Bordeaux, Marseille
2025-09-29
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
Saint-Herblain, Toulouse, Villejuif
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Bordeaux, Lyon, Dijon, Toulouse, Montpellier, Rennes, Saint-Herblain, Reims
2025-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
182
La Tronche, Saint-Herblain, Vandœuvre-lès-Nancy, Bron, Paris
2025-09-09
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bordeaux, Brest, Dijon, Lille, Lyon, Paris, Pierre-Bénite, Saint-Herblain
2025-09-02
Active, closed
Amgen
Phase 3
350
Créteil, Lyon, Marseille, Paris, Saint-Herblain, Toulon, Toulouse
2025-08-18
Recruiting
GlaxoSmithKline
Phase 3
420
Boulogne-Billancourt, Grenoble, Saint-Herblain, Villejuif
2025-08-11
Recruiting
AstraZeneca
Phase 2
278
Avignon, Paris, Rennes, Saint-Herblain, Suresnes
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Paris, Saint-Herblain
2025-08-06
Recruiting
dsm-firmenich Switzerland AG
Not applicable
236
Paris, Saint-Herblain
2025-08-01
Recruiting
Pfizer
Phase 3
714
Pessac, Quimper, Toulouse, Rennes, Montpellier, Saint-Herblain, Cholet, Toulon
2025-07-23
Recruiting
Bristol-Myers Squibb
Phase 3
586
Marseille, Tours, Toulouse, Lille, Rennes, Saint-Herblain, Nancy, Bron
2025-07-21
Active, closed
Compugen Ltd
Phase 1/2
60
Besançon, Toulouse, Lille, Marseille, Pierre-Bénite, Rennes, Saint-Herblain, Villejuif
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Bordeaux, Lille, Saint-Herblain, Bayonne, Pierre-Bénite
2025-07-03
Recruiting
Institut de Cancérologie de Lorraine
Not applicable
598
Brest, Rouen, Saint-Herblain, Vandœuvre-lès-Nancy
2025-07-02
Recruiting
Pfizer
Phase 2
620
Montpellier, Saint-Herblain, Toulon, Grenoble
2025-06-19
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Bron, Dijon, Marseille, Paris, Saint-Herblain
2025-06-10
Recruiting
BioNTech SE
Phase 3
480
Angers, Besançon, Caen, Le Mans, Marseille, Paris, Saint-Herblain, Strasbourg
2025-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Marseille, Caen, Plérin, Bordeaux, Toulouse, Saint-Cloud, Saint-Herblain, Lyon
2025-05-22
Recruiting
Eikon Therapeutics
Phase 2/3
740
Pierre-Bénite, Boulogne, La Tronche, Lille, Marseille, Nice, Paris, Saint-Herblain
2025-05-22
Recruiting
Institut Cancerologie de l'Ouest
Not applicable
63
Angers, Cholet, Saint-Herblain
2025-05-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Strasbourg, Marseille, Montpellier, Rennes, La Tronche, Saint-Herblain, Léon, Lille
2025-05-06
Recruiting
Institut Cancerologie de l'Ouest
Phase 3
84
Brest, Caen, Chambray-lès-Tours, Dijon, Le Havre, Lyon, Rennes, Saint-Herblain
2025-04-29
Recruiting
BioNTech SE
Phase 1/2
380
Besançon, Le Mans, Saint-Herblain, Toulouse
2025-04-23
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Nice, Montpellier, Saint-Herblain, Angers, Rouen, Le Kremlin-Bicêtre
2025-04-16
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Bordeaux, Saint-Herblain
2025-04-03
Recruiting
AstraZeneca
Phase 3
990
Brest, Lyon, Marseille, Montpellier, Paris, Pessac, Saint-Herblain
2025-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Lyon, Limoges, Montpellier, Saint-Herblain, Reims, Rouen, Toulon, Paris
2025-03-16
Recruiting
AbbVie
Phase 1/2
252
Bordeaux, Saint-Herblain, Montpellier, Nice, Villejuif, Paris
2025-03-06
Not yet open
Predict CHimio-or Radiation-induced NAusea and Vomiting in Children/adolescents Treated for Cancer
NCT06869005Childhood Cancer, Nausea with Vomiting Chemotherapy-Induced
Rennes University Hospital
Observational
150
Angers, Caen, Rennes, Saint-Herblain, Tours
2025-03
Active, closed
Genmab
Phase 3
584
Nice, Paris, Pierre-Bénite, Rennes, Saint-Herblain, Toulouse, Villejuif
2025-02-07
Recruiting
BioNTech SE
Phase 3
621
Angers, Bordeaux, Caen, Paris, Rennes, Saint-Herblain, Toulon
2025-02-03
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Bordeaux, Dijon, Lille, Paris, Saint-Herblain, Suresnes, Toulouse, Villejuif
2025-01-29
Recruiting
BeOne Medicines
Phase 1
695
Bordeaux, Marseille, Paris, Saint-Herblain, Villejuif
2025-01-10
Recruiting
Institut Claudius Regaud
Not applicable
130
Angers, Bordeaux, Limoges, Nîmes, Saint-Herblain, Toulouse
2025-01-08
Active, closed
Daiichi Sankyo
Phase 2
335
Caen, Dijon, Lille, Lyon, Paris, Plérin, Saint-Herblain, Toulouse
2025-01-06
Active, closed
Pfizer
Phase 3
1,035
Bayonne, Bordeaux, Lille, Saint-Cloud, Rennes, Montpellier, Saint-Herblain, Angers
2025-01-06
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
DrugsPalazestrant·Fulvestrant
Olema Pharmaceuticals, Inc.
Phase 1
180
Saint-Herblain, Paris, Villejuif
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Brest, La Tronche, Marseille, Saint-Herblain
2024-12-16
Recruiting
Hospices Civils de Lyon
Not applicable
722
Bron, Dijon, Montpellier, Nancy, Paris, Pessac, Rennes, Saint-Herblain
2024-12-12
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsTORL-1-23·Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2
230
Lyon, Saint-Herblain, Villejuif
2024-11-20
Recruiting
Centre Leon Berard
Not applicable
100
Angers, Bourg-en-Bresse, Dijon, Grenoble, Lyon, Marseille, Nice, Saint-Herblain
2024-11-15
Not yet open
Assessing the Ompact of Neutral Pelvic Positioning on Bone Repositioning Quality in Pelvic Radiotherapy Patients
NCT06687200Radiotherapy, Repositonning Pelvic, Neutral Pelvic Positioning
Centre Leon Berard
Not applicable
200
Lyon, Nancy, Rennes, Saint-Herblain
2024-11-15
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
Montpellier, Saint-Cloud, Saint-Herblain, Bordeaux, Lyon, Villejuif
2024-10-29
Recruiting
Pfizer
Phase 3
900
Bordeaux, Lyon Cedex08, Strasbourg, Brest, Saint-Grégoire, Saint-Herblain, Reims, Le Mans
2024-10-22
Recruiting
Pierre Fabre Medicament
Phase 1/2
140
Marseille, Saint-Herblain, Toulouse, Villejuif
2024-10-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Caen, Tours, Besançon, Saint-Herblain, Lille, Lyon, Paris, Villejuif
2024-10-21
By invitation
Institut des Hautes Etudes Osteopathiques de Nantes
Observational
400
Saint-Herblain
2024-10-15
Active, closed
SynOx Therapeutics Limited
Phase 3
128
Bordeaux, Saint-Herblain, Paris, Lyon, Lille, Toulouse
2024-10-09
Active, closed
Amgen
Phase 1
49
Bordeaux, Marseille, Saint-Herblain, Villejuif
2024-09-17
Recruiting
Pierre Fabre Medicament
Phase 1/2
171
Lyon, Marseille, Saint-Herblain, Toulouse, Villejuif
2024-09-17
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Bordeaux, Dijon, Lille, Saint-Cloud, Saint-Herblain, Vandœuvre-lès-Nancy
2024-08-31
Active, closed
Gilead Sciences
Phase 3
640
Caen, Marseille, Nice, Paris, Pierre-Bénite, Saint-Herblain, Vandœuvre-lès-Nancy, Villejuif
2024-08-28
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
Grenoble, Saint-Herblain, Villejuif
2024-08-14
Recruiting
Institut du Cancer de Montpellier - Val d'Aurelle
Not applicable
264
Saint-Herblain, Vandœuvre-lès-Nancy, Lyon, Montpellier, Nice, Nîmes, Paris, Toulouse
2024-08-09
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
102
Dijon, Grenoble, Marseille, Saint-Herblain, Villejuif
2024-08-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Montpellier, Saint-Herblain, Bron
2024-08-05
Recruiting
AstraZeneca
Phase 3
788
Angers, Besançon, Lille, Lyon, Marseille, Paris, Rouen, Saint-Herblain
2024-08-01
Recruiting
Daiichi Sankyo
Phase 1/2
123
Lille, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Suresnes, Villejuif
2024-07-22
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Nancy, Saint-Herblain, Bordeaux, Limoges, Boulogne-Billancourt, Dijon, Nantes, Vantoux
2024-07-16
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Bordeaux, Lille, Lyon, Marseille, Paris, Saint-Herblain, Strasbourg, Toulouse
2024-07-09
Recruiting
GlaxoSmithKline
Phase 1
675
Lyon, Saint-Herblain, Villejuif
2024-07-02
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Bordeaux, Caen, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Strasbourg
2024-06-28
Recruiting
GERCOR - Multidisciplinary Oncology Cooperative Group
Not applicable
72
Dijon, Grenoble, Lille, Marseille, Reims, Rouen, Saint-Cloud, Saint-Herblain
2024-06-24
Active, closed
Ivy Brain Tumor Center
Phase 3
450
Nice, Marseille, Montpellier, Rennes, Saint-Herblain, Paris, Bron, Lyon
2024-06-19
Active, closed
Kumquat Biosciences Inc.
Phase 1
92
Marseille, Saint-Herblain, Bordeaux, Toulouse, Nantes
2024-06-03
Active, closed
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification
DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab
Enliven Therapeutics
Phase 1
275
Montpellier, Poitiers, Saint-Herblain, Strasbourg
2024-05-30
Recruiting
Centre Oscar Lambret
Not applicable
377
Lyon, Besançon, Rennes, Strasbourg, Lille, Poitiers, Toulouse, Saint-Herblain
2024-05-29
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Lyon, Saint-Herblain, Toulouse
2024-05-20
Active, closed
Institut Cancerologie de l'Ouest
Not applicable
88
Saint-Herblain
2024-05-16
Active, closed
Hoffmann-La Roche
Phase 2
256
Bron, Lille, Marseille, Paris, Rouen, Saint-Herblain, Strasbourg, Toulouse
2024-05-02
Recruiting
Daiichi Sankyo
Phase 1/2
680
Dijon, Bordeaux, Montpellier, Rennes, Saint-Herblain, Paris, Lyon, Villejuif
2024-04-10
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
Lyon, Paris, Saint-Herblain, Villejuif
2024-04-03
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Montpellier, Poitiers, Saint-Herblain, Villejuif
2024-04-01
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
212
Avignon, Lyon, Marseille, Mâcon, Nice, Saint-Etienne, Saint-Herblain, Villejuif
2024-03-26
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Dijon, Saint-Herblain, Toulouse
2024-03-25
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Amiens, Clermont-Ferrand, Lille, Lyon, Montpellier, Nice, Paris, Saint-Herblain
2024-03-15
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Saint-Cloud, Bordeaux, Bron, Clermont-Ferrand, Rouen, Saint-Herblain
2024-03-12
Recruiting
DEprescribing: Perceptions of PAtients Living With Advanced Cancer
NCT06193083Deprescribing, Palliative Care, Oncology
Nantes University Hospital
Observational
325
La Roche-sur-Yon, Lyon, Nantes, Paris, Saint-Herblain, Saint-Nazaire, Tours
2024-02-28
Recruiting
Elsan
Not applicable
132
Beaumont, Caen, Essey-lès-Nancy, Lyon, Muret, Nice, Saint-Herblain, Strasbourg
2024-02-27
Active, closed
Pfizer
Phase 1/2
71
Montpellier, Saint-Herblain, Marseille
2024-02-19
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Grenoble, Pessac, Saint-Herblain, Angers, Lorient, Nantes, Poitiers, Nice
2024-02-01
Recruiting
FH ORTHO
Not applicable
800
Guilherand-Granges, Oyonnax, Reims, Rennes, Saint-Herblain
2024-01-08
Active, closed
Bristol-Myers Squibb
Phase 3
190
Strasbourg, Pessac, Dijon, Rouen, La Tronche, Saint-Herblain, Pierre-Bénite, Paris
2023-12-21
Recruiting
AstraZeneca
Phase 3
1,145
Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif
2023-12-14
Active, closed
Sanofi
Phase 3
1,655
Calais, Colmar, La Tronche, Lille, Nice, Saint-Herblain
2023-12-13
Active, closed
Sanofi
Phase 2
197
Corbeil-Essonnes, Mont-de-Marsan, Paris, Pontoise, Saint-Herblain
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Bordeaux, Caen, Lille, Marseille, Paris, Rennes, Saint-Herblain, Villejuif
2023-12-01
Recruiting
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
NCT05872204Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
DrugsAbemaciclib·Letrozole
Universitaire Ziekenhuizen KU Leuven
Phase 2
100
Strasbourg, Bordeaux, Toulouse, Saint-Herblain, Lyon, Paris
2023-11-30
Recruiting
Institut Claudius Regaud
Phase 2
48
Bordeaux, Lille, Limoges, Lyon, Montpellier, Paris, Poitiers, Saint-Herblain
2023-11-28
Recruiting
AstraZeneca
Phase 3
625
Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
2023-11-23
Active, closed
Novartis Pharmaceuticals
Phase 1
28
Saint-Cloud, Bordeaux, Saint-Herblain
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 1
33
Dijon, Clermont-Ferrand, Lyon, Nantes, Saint-Herblain, Vandœuvre-lès-Nancy
2023-11-07
Recruiting
Institut Cancerologie de l'Ouest
Not applicable
300
Angers, Saint-Herblain
2023-10-31
Recruiting
Sanofi
Phase 3
180
Le Plessis-Robinson, Marseille, Paris, Pessac, Saint-Herblain, Strasbourg, Suresnes
2023-10-10
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
Saint-Herblain, Toulouse, Villejuif
2023-09-26
Recruiting
Institut Cancerologie de l'Ouest
Not applicable
200
Saint-Herblain
2023-09-12
Active, closed
Cytokinetics
Phase 3
500
Marseille, Montpellier, Paris, Pessac, Saint-Herblain, Toulouse
2023-08-31
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Lyon, Marseille, Saint-Herblain, Strasbourg, Toulouse, Villejuif
2023-08-18
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
DrugIza-bren
SystImmune Inc.
Phase 1
540
Lyon, Paris, Saint-Herblain, Villejuif
2023-08-08
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Strasbourg, Lyon, Caen, Limoges, Pessac, Marseille, Saint-Herblain, Boulogne-Billancourt
2023-07-31
Recruiting
REGEnLIFE SAS
Not applicable
108
Castres, Lavaur, Paris, Saint-Herblain, Toulouse, Villeurbanne
2023-07-24
Active, closed
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach
NCT05928416Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis
ZIWIG
Observational
653
Strasbourg, Saint-Herblain, Saint-Étienne-de-Montluc, Bron, Angers, Bordeaux, Brest, Caen
2023-07-11
Not yet open
Assessment and Prevention of Caregiver Burden in Oncology
NCT05750836Oncology, Caregiver Burden
Institut Cancerologie de l'Ouest
Not applicable
250
Cholet, Nice, Rouen, Saint-Herblain, Saint-Lô
2023-07
Recruiting
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer
NCT06896890NSCLC (advanced Non-small Cell Lung Cancer), Stage IV Lung Cancer
Inhatarget Therapeutics
Phase 1/2
32
Boulogne-Billancourt, Caen, Paris, Saint-Herblain
2023-06-23
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
225
Brest, Lyon, Saint-Herblain, Villejuif
2023-05-26
Active, closed
Grey Wolf Therapeutics
Phase 1/2
300
Lyon, Marseille, Rennes, Saint-Herblain, Strasbourg, Toulouse, Villejuif
2023-05-21
Recruiting
Institut Cancerologie de l'Ouest
Not applicable
200
Angers, Saint-Herblain
2023-04-24
Active, closed
University Hospital, Strasbourg, France
Not applicable
200
Lyon, Nantes, Nice, Reims, Strasbourg, Marseille, Rennes, Saint-Herblain
2023-04-04
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Saint-Herblain, Toulouse
2023-03-17
Active, closed
Pfizer
Phase 3
624
Dijon, Montpellier, Saint-Herblain, Angers, Clermont-Ferrand, Avignon, Poitiers, Créteil
2023-03-03
Recruiting
Institut Bergonié
Phase 2
62
Avignon, Besançon, Bordeaux, Brest, Marseille, Paris, Saint-Grégoire, Saint-Herblain
2023-02-24
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugIMGN151
AbbVie
Phase 1
256
Saint-Herblain, Nice, Lyon, Pierre-Bénite, Villejuif
2023-01-11
Recruiting
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
NCT05751798Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
OSE Immunotherapeutics
Phase 1/2
41
Lyon, Paris, Rennes, Saint-Herblain, Toulouse, Villejuif
2022-12-20
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
885
Bron, Dijon, Marseille, Montpellier, Paris, Saint-Herblain, Strasbourg, Valenciennes
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Lille, Marseille, Saint-Herblain, Strasbourg
2022-12-13
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Marseille, Bron, Montpellier, Saint-Herblain, Strasbourg
2022-12-06
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 1/2
310
Saint-Herblain, Toulouse, Villejuif
2022-11-22
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Caen, Dijon, Nîmes, Paris, Saint-Herblain, Villejuif
2022-11-11
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Paris, Pierre-Bénite, Saint-Herblain, Strasbourg, Vénissieux
2022-11-01
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
Lyon, Strasbourg, Bordeaux, Caen, Montpellier, Angers, Saint-Herblain, Paris
2022-10-14
Active, closed
Gilead Sciences
Phase 3
1,021
Boulogne-Billancourt, Le Mans, Marseille, Montpellier, Saint-Herblain, Saint-Mandé, Saint-Quentin, Suresnes
2022-10-12
Active, closed
Bayer
Phase 1
129
Lille, Bordeaux, Saint-Herblain, Villejuif
2022-10-11
Recruiting
Elsan
Not applicable
172
Pessac, Saint-Herblain
2022-09-29
Active, closed
Genetics of Ventriculo-arterial Discordance
NCT05330338Heart Defects, Congenital
Nantes University Hospital
Not applicable
600
Marseille, Rennes, Bordeaux, Toulouse, Lille, Le Plessis-Robinson, Nantes, Saint-Herblain
2022-09-07
Recruiting
Acrivon Therapeutics
Phase 2
350
Caen, Lyon, Saint-Herblain, Villejuif
2022-08-29
Active, closed
Biogen
Phase 2
416
Strasbourg, Toulouse, Montpellier, Saint-Herblain, Lille, Paris, Rouen
2022-08-24
Active, closed
Amgen
Phase 1
184
Lyon, Saint-Herblain, Villejuif
2022-08-24
Recruiting
Bristol-Myers Squibb
Observational
1,700
Haguenau, Saint-Herblain, Lille, Amiens, Toulon, Poitiers, Montpellier
2022-08-16
Active, closed
Daiichi Sankyo
Phase 3
586
Brest, Caen, Lyon, Montpellier, Paris, Pierre-Bénite, Rennes, Saint-Herblain
2022-07-08
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
398
Vaillant, Lyon, Marseille, Poitiers, Saint-Herblain, Toulouse
2022-06-07
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Bordeaux, Dijon, Marseille, Nantes, Paris, Poitiers, Saint-Herblain, Suresnes
2022-05-25
Active, closed
Eli Lilly and Company
Phase 1
260
Lyon, Paris, Saint-Herblain, Strasbourg, Villejuif
2022-05-11
Recruiting
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
NCT05182164Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma
DrugCabozantinib
Institut Bergonié
Phase 2
119
Bordeaux, Dijon, Lille, Lyon, Marseille, Paris, Saint-Herblain, Toulouse
2022-04-25
Active, closed
Eli Lilly and Company
Phase 3
925
Lyon, Brest, La Chaussée-Saint-Victor, Dijon, Besançon, Montpellier, Nantes, Saint-Herblain
2022-04-14
Recruiting
Cogent Biosciences, Inc.
Phase 3
482
Bordeaux, Lille, Lyon, Marseille, Rennes, Saint-Herblain, Toulouse, Villejuif
2022-04-14
Active, closed
AstraZeneca
Phase 3
1,035
Bordeaux, Brest, Clermont-Ferrand, Créteil, Montpellier, Paris, Rouen, Saint-Herblain
2022-03-25
Active, closed
Centre Jean Perrin
Phase 1/2
66
Brest, Clermont-Ferrand, Grenoble, Lyon, Paris, Saint-Herblain, Strasbourg, Villejuif
2022-03-07
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Rouen, Bordeaux, Montpellier, Saint-Herblain, Avignon, Dijon, Besançon, Bobigny
2022-03-07
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2
310
Nice, Dijon, Besançon, Brest, Toulouse, Lille, Paris, Saint-Herblain
2022-02-17
Recruiting
Centre Hospitalier Departemental Vendee
Not applicable
526
Bayonne, La Roche-sur-Yon, Le Puy-en-Velay, Nantes, Orléans, Rennes, Saint-Herblain
2021-12-07
Recruiting
Adult Tic Disorders Registry
NCT05090943Tic Disorders
Assistance Publique - Hôpitaux de Paris
Observational
450
Clermont-Ferrand, Limoges, Marseille, Paris, Poitiers, Saint-Herblain, Strasbourg
2021-12-01
Recruiting
Leiden University Medical Center
Phase 3
316
Besançon, Bordeaux, Lyon, Marseille, Montpellier, Nice, Saint-Herblain, Strasbourg
2021-11-11
Recruiting
Bayer
Phase 1/2
430
Lyon, Bordeaux, Nantes, Saint-Herblain, Marseille, Paris, Villejuif
2021-10-25
Active, closed
Boehringer Ingelheim
Phase 1
151
Bordeaux, Dijon, Saint-Herblain
2021-10-18
Active, closed
AbbVie
Phase 1
520
Bordeaux, Saint-Herblain, Nice, Lyon, Villejuif, Dijon, Paris
2021-10-13
Active, closed
Hoffmann-La Roche
Phase 2
176
Besançon, Caen, Lyon, Paris, Rennes, Saint-Herblain, Toulouse, Villejuif
2021-10-07
Active, closed
Tooth Retention After Root Canal Treatment With Endomethasone N
NCT04945993Dental Root Canal Obturation
Septodont
Observational
179
Athis-Mons, Dax, Montélimar, Saint-Herblain, Valence
2021-07-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Lyon, Marseille, Caen, Besançon, Toulouse, Montpellier, Saint-Herblain, Angers
2021-06-18
Active, closed
Centre Jean Perrin
Not applicable
1,100
Clermont-Ferrand, Beaumont, Angers, Rennes, Saint-Herblain, Paris
2021-05-31
Active, closed
CNS Pharmaceuticals, Inc.
Phase 2
252
Lyon, Marseille, Montpellier, Paris, Saint-Herblain, Toulouse, Villejuif
2021-05-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Nice, Pessac, Strasbourg, Brest, Toulouse, Lille, La Tronche, Saint-Herblain
2021-05-12
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
139
Dijon, Limoges, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain
2021-05-11
Active, closed
AstraZeneca
Phase 3
893
Bobigny, Limoges, Lyon, Plérin, Rouen, Saint-Herblain, Villejuif
2021-05-10
Recruiting
Gilead Sciences
Phase 1
30
Bordeaux, Lyon, Saint-Herblain
2021-04-06
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
La Roche-sur-Yon, Lille, Lyon, Nîmes, Paris, Pierre-Bénite, Rennes, Saint-Herblain
2021-03-18
Recruiting
AstraZeneca
Phase 1
304
Bordeaux, Dijon, Pierre-Bénite, Saint-Herblain, Villejuif
2021-03-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Reims, Nice, Strasbourg, Bordeaux, Toulouse, Limoges, Saint-Herblain, Angers
2021-02-25
Recruiting
Institut Cancerologie de l'Ouest
Phase 2
262
Angers, Bordeaux, Montpellier, Nice, Paris, Saint-Herblain, Toulouse
2021-02-03
Recruiting
Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction
NCT04342546Breast Cancer, Capsular Contracture Associated With Breast Implant
Institut du Cancer de Montpellier - Val d'Aurelle
Not applicable
250
Dijon, Lille, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain
2020-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Saint-Quentin, Bordeaux, Marseille, Grenoble, Saint-Herblain, Angers, Bobigny, Toulon
2020-12-08
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
Strasbourg, Bordeaux, Toulouse, Saint-Herblain, Clermont-Ferrand, Villejuif, Lyon, Nîmes
2020-10-29
Active, closed
Hoffmann-La Roche
Phase 1/2
210
Toulouse, Dijon, Lille, Lyon, Marseille, Saint-Herblain, Villejuif
2020-09-03
Active, closed
University Hospital, Tours
Not applicable
100
Angers, Rennes, Saint-Herblain, Tours
2020-09-01
Recruiting
University Hospital, Toulouse
Phase 3
310
Bordeaux, Clermont-Ferrand, Créteil, Marseille, Pierre-Bénite, Poitiers, Saint-Herblain, Saint-Pierre
2020-07-17
Active, closed
Novartis Pharmaceuticals
Phase 3
19
Saint-Cloud, Saint-Herblain
2020-07-16
Recruiting
High Resolution Imaging for Analysis of MVNT
NCT04285125Benign Neuronal Desease
Fondation Ophtalmologique Adolphe de Rothschild
Observational
33
Bordeaux, Rennes, Rouen, Toulouse, Paris, Pierre-Bénite, Saint-Herblain
2020-03-05
Recruiting
Stryker Trauma and Extremities
Observational
417
Lyon, Paris, Saint-Herblain
2019-11-14
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bordeaux, Lille, Lyon, Nantes, Saint-Herblain, Strasbourg, Villejuif
2019-09-18
Active, closed
AstraZeneca
Phase 3
923
Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif
2019-06-25
Active, closed
AbbVie
Phase 1
150
Saint-Herblain, Paris, Lyon, Clermont-Ferrand
2019-05-21
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
Clermont, Saint-Herblain, Bordeaux, Caen, Marseille, Paris, Pierre-Bénite, Poitiers
2019-03-20
Recruiting
Institut Bergonié
Phase 3
351
Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Saint-Herblain, Strasbourg
2019-02-14
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
453
Bordeaux, Dijon, Lille, Lyon, Marseille, Paris, Poitiers, Saint-Herblain
2019-02-08
Active, closed
AstraZeneca
Phase 3
1,407
Besançon, Bordeaux, Limoges, Lyon, Marseille, Nantes, Paris, Saint-Herblain
2019-01-04
Active, closed
9-ING-41 in Patients With Advanced Cancers
NCT03678883Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
DrugsCCNU·Lomustine·Abraxane·Adriamycin
Actuate Therapeutics Inc.
Phase 2
350
Besançon, Brest, Lille, Vandœuvre-lès-Nancy, Bordeaux, Saint-Herblain, Marseille
2019-01-04
Active, closed
Institut Cancerologie de l'Ouest
Not applicable
289
Angers, Saint-Herblain
2018-12-24
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Dijon, Brest, Rennes, Besançon, Montpellier, Paris, Saint-Herblain, Nice
2018-06-21
Active, closed
AstraZeneca
Phase 1
117
Bordeaux, Caen, Lyon, Marseille, Saint-Herblain, Toulouse
2016-12-28
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Bordeaux, La Roche-sur-Yon, Lille, Lyon, Montpellier, Nîmes, Paris, Saint-Herblain
2016-12-22
Active, closed
Eisai Inc.
Phase 3
1,069
Angers, Dijon, Le Mans, Lyon, Montpellier, Paris, Saint-Herblain, Strasbourg
2016-10-13
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Pessac, Toulouse, Saint-Herblain, Saint-Nazaire, Angers, Cholet, Lorient, Lille
2016-09-13
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Bordeaux, Dijon, Lyon, Marseille, Paris, Saint-Herblain, Villejuif
2016-05-24
Active, closed
Tesaro, Inc.
Phase 1
729
Bordeaux, Caen, Clermont-Ferrand, Lille, Marseille, Paris, Saint-Herblain, Villejuif
2016-03-07
Active, closed
Institut Cancerologie de l'Ouest
Not applicable
769
Nantes, Saint-Herblain, Villejuif
2016-01
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Paris, Saint-Herblain, Strasbourg, Villejuif
2015-12-11
Active, closed
Phase III Radium 223 mCRPC-PEACE III
NCT02194842Prostate Cancer
DrugsRa223·Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
446
Angers, Caen, Créteil, Lyon, Montpellier, Saint-Herblain, Strasbourg, Villejuif
2015-10
Active, closed
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
NCT02243605Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma
DrugsCabozantinib S-malate·Cabozantinib
National Cancer Institute (NCI)
Phase 2
90
Bordeaux, Dijon, Lille, Lyon, Marseille, Nice, Paris, Saint-Herblain
2014-12-19
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Angers, Caen, Dijon, Le Mans, Lyon, Montpellier, Paris, Saint-Herblain
2014-11-26
Active, closed
Eli Lilly and Company
Phase 3
493
Bordeaux, Lyon, Brest, Dijon, Saint-Brieuc, Montpellier, Saint-Herblain, Nancy
2014-11-06
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bordeaux, Lyon, Saint-Herblain, Villejuif
2014-10-31
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Marseille, Paris, Saint-Herblain
2013-10-22
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Caen, Créteil, Lyon, Nantes, Paris, Poitiers, Saint-Herblain, Suresnes
2012-04-03
Active, closed
Genentech, Inc.
Phase 2
378
Caen, Dijon, Marseille, Montpellier, Paris, Saint-Cloud, Saint-Herblain
2008-10-16
Rows per page Showing 1–243 of 243
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-france/city/saint-herblain

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,722 studies in total at the last sync on 29 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 243 of those studies with a site in Saint-Herblain.

How many clinical trials are recruiting in Saint-Herblain?

135 of the 243 studies on this page are recruiting new participants as of the 29 Oct 2026, 03:20 UTC sync. A further 12 have not yet opened recruitment, 95 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Saint-Herblain), 243 studies
PhaseStudiesRecruitingShare
Phase 3784032.1%
Phase 2382215.6%
Phase 1/2372315.2%
Not applicable352314.4%
Phase 1341514%
Observational1475.8%
Phase 2/3552.1%
Early Phase 1100.4%
Phase 4100.4%

Most active sponsors

Lead sponsors with the most studies (Saint-Herblain)
Lead sponsorStudiesRecruiting
Institut Cancerologie de l'Ouest178
AstraZeneca158
Novartis Pharmaceuticals124
Bristol-Myers Squibb1110
Merck Sharp & Dohme LLC104
Pfizer85
Daiichi Sankyo64
Hoffmann-La Roche62
Janssen Research & Development, LLC64
AbbVie52
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.